Morphology of myeloproliferative neoplasms

被引:8
作者
Ng, Zi Yun [1 ,2 ]
Fuller, Kathryn A. [1 ]
Mazza-Parton, Allegra [1 ]
Erber, Wendy N. [1 ,3 ,4 ]
机构
[1] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia
[2] Royal Perth Hosp, Haematol Dept, Perth, WA, Australia
[3] PathWest Lab Med, Dept Haematol, Nedlands, WA, Australia
[4] Univ Western Australia, Sch Biomed Sci M504, Crawley, WA 6009, Australia
关键词
essential thrombocythaemia; myelofibrosis; myeloproliferative neoplasms; polycythaemia vera; BONE-MARROW FIBROSIS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; EUROPEAN CONSENSUS; MYELOFIBROSIS; MUTATIONS; DISEASE; JAK2; PROGRESSION; ANAGRELIDE;
D O I
10.1111/ijlh.14086
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease progression. The blood film changes may be in any of the cellular elements. The key bone marrow features are architecture and cellularity, relative complement of individual cell types, reticulin content and bony structure. Megakaryocytes are the most abnormal cell and key to classification, as their number, location, size and cytology are all disease-defining. Reticulin content and grade are integral to assignment of the diagnosis of myelofibrosis. Even with careful assessment of all these features, not all cases fit neatly into the diagnostic entities; there is frequent overlap reflecting the biological disease continuum rather than distinct entities. Notwithstanding this, an accurate morphologic diagnosis in MPN is crucial due to the significant differences in prognosis between different subtypes and the availability of different therapies in the era of novel agents. The distinction between "reactive" and MPN is also not always straightforward and caution needs to be exercised given the prevalence of "triple negative" MPN. Here we describe the morphology of MPN including comments on changes with disease evolution and with treatment.
引用
收藏
页码:59 / 70
页数:12
相关论文
共 31 条
  • [1] Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
    Barbui, Tiziano
    Thiele, Juergen
    Passamonti, Francesco
    Rumi, Elisa
    Boveri, Emanuela
    Randi, Maria Luigia
    Bertozzi, Irene
    Marino, Filippo
    Vannucchi, Alessandro M.
    Pieri, Lisa
    Rotunno, Giada
    Gisslinger, Heinz
    Gisslinger, Bettina
    Muellauer, Leonhard
    Finazzi, Guido
    Carobbio, Alessandra
    Gianatti, Andrea
    Ruggeri, Marco
    Nichele, Ilaria
    D'Amore, Emanuele
    Rambaldi, Alessandro
    Tefferi, Ayalew
    [J]. BLOOD, 2012, 119 (10) : 2239 - 2241
  • [2] Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
    Barbui, Tiziano
    Thiele, Juergen
    Passamonti, Francesco
    Rumi, Elisa
    Boveri, Emanuela
    Ruggeri, Marco
    Rodeghiero, Francesco
    d'Amore, Emanuele S. G.
    Randi, Maria Luigia
    Bertozzi, Irene
    Marino, Filippo
    Vannucchi, Alessandro M.
    Antonioli, Elisabetta
    Carrai, Valentina
    Gisslinger, Heinz
    Buxhofer-Ausch, Veronika
    Muellauer, Leonhard
    Carobbio, Alessandra
    Gianatti, Andrea
    Gangat, Naseema
    Hanson, Curtis A.
    Tefferi, Ayalew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) : 3179 - 3184
  • [3] Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
    Campbell, PJ
    Scott, LM
    Buck, G
    Wheatley, K
    East, CL
    Marsden, JT
    Duffy, A
    Boyd, EM
    Bench, AJ
    Scott, MA
    Vassiliou, GS
    Milligan, DW
    Smith, SR
    Erber, WN
    Bareford, D
    Wilkins, BS
    Reilly, JT
    Harrison, CN
    Green, AR
    [J]. LANCET, 2005, 366 (9501) : 1945 - 1953
  • [4] The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
    Gianelli, Umberto
    Vener, Claudia
    Bossi, Anna
    Cortinovis, Ivan
    Iurlo, Alessandra
    Fracchiolla, Nicola S.
    Savi, Federica
    Moro, Alessia
    Grifoni, Federica
    De Philippis, Chiara
    Radice, Tommaso
    Bosari, Silvano
    Deliliers, Giorgio Lambertenghi
    Cortelezzi, Agostino
    [J]. MODERN PATHOLOGY, 2012, 25 (09) : 1193 - 1202
  • [5] Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
    Guglielmelli, Paola
    Pacilli, Annalisa
    Rotunno, Giada
    Rumi, Elisa
    Rosti, Vittorio
    Delaini, Federica
    Maffioli, Margherita
    Fanelli, Tiziana
    Pancrazzi, Alessandro
    Pietra, Daniela
    Salmoiraghi, Silvia
    Mannarelli, Carmela
    Franci, Annalisa
    Paoli, Chiara
    Rambaldi, Alessandro
    Passamonti, Francesco
    Barosi, Giovanni
    Barbui, Tiziano
    Cazzola, Mario
    Vannucchi, Alessandro M.
    [J]. BLOOD, 2017, 129 (24) : 3227 - 3236
  • [6] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
    Harrison, CN
    Campbell, PJ
    Buck, G
    Wheatley, K
    East, CL
    Bareford, D
    Wilkins, BS
    van der Walt, JD
    Reilly, JT
    Grigg, AP
    Revell, P
    Woodcock, BE
    Green, AR
    Pearson, TC
    Conneally, E
    Crawley, C
    Cross, NCP
    Hall, G
    Hunt, B
    Lucas, G
    Ludlam, C
    McMullin, MF
    Oscier, D
    Radia, D
    Reilly, JT
    Robinson, G
    Culligan, DJ
    Tighe, J
    Watson, HG
    Warren, AJ
    Awaad, MO
    Obeid, D
    Cuthbert, RJG
    Kyle, A
    Chan-Lam, D
    Paul, B
    Cuthbert, RJG
    McMullin, MF
    Morris, TCM
    Johnson, RJ
    Fegan, C
    Milligan, DW
    Galloway, MJ
    Williamson, PJ
    Newton, LJ
    Williams, AT
    Abboudi, Z
    Ryan, K
    Lush, R
    Blundell, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) : 33 - 45
  • [7] Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment
    Hultdin, Magnus
    Sundstrom, Gunnel
    Wahlin, Anders
    Lundstrom, Berith
    Birgegard, Gunnar
    Engstrom-Laurent, Anna
    [J]. MEDICAL ONCOLOGY, 2007, 24 (01) : 63 - 70
  • [8] Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
    Jamieson, Catriona
    Hasserjian, Robert
    Gotlib, Jason
    Cortes, Jorge
    Stone, Richard
    Talpaz, Moshe
    Thiele, Juergen
    Rodig, Scott
    Pozdnyakova, Olga
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [9] Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
    Kvasnicka, Hans Michael
    Thiele, Juergen
    Bueso-Ramos, Carlos E.
    Sun, William
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [10] Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
    Larsen, Thomas Stauffer
    Moller, Michael Boe
    de Stricker, Karin
    Norgaard, Peter
    Samuelsson, Jan
    Marcher, Claus
    Andersen, Morten T.
    Bjerrum, Ole Weis
    Hasselbalch, Hans Carl
    [J]. HEMATOLOGY, 2009, 14 (06) : 331 - 334